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Objective: A transdermal hydrogel dosage form consists of a three-dimensional polymer network that binds water in large quantities and is used 
for drug delivery. The study’s aim was to prepare coprocessed excipients as a matrix for a transdermal hydrogel containing diclofenac sodium and 
examine in vitro and in vivo drug penetrations.
Methods: Four types of coprocessed excipients were produced using two methods that combined crosslinking and coprocessing steps. The produced 
excipients were formulated as transdermal gels containing sodium diclofenac. An in vitro penetration test was then performed using a Franz diffusion 
cell to pass the drug through a rat skin membrane. An in vivo penetration test was performed by applying the hydrogel to the abdominal skin of male 
Sprague-Dawley rats and then measuring the plasma drug concentration.
Results: In vitro penetration results showed that the flux from Co-CLA6-XG 1:2, Co-CLA12-XG 1:2, CL6-Co-A-XG 1:2, and CL12-Co-A-XG 1:2 transdermal 
hydrogels was 655.23±116.43 µg∙cm−2/h, 569.08±26.58 µg∙cm−2/h, 867.42±101.27 μg∙cm−2/h−1, and 736.99±15.39 µg∙cm−2/h−1. The in vivo study 
resulted in area under the curve for the Co−CLA6−XG 1:2, Co−CLA12−XG 1:2, CL6−Co−A−XG 1:2, and CL12−Co−A−XG 1:2 transdermal hydrogels was 
32.08±5.40 µg∙ml−1∙h, 34.27±8.34 µg/ml∙h, 6.20±2.90 µg/ml∙h, and 14.38±2.38 µg/mL∙h, respectively.
Conclusion: The study results showed that the excipients could be processed to form a matrix within a transdermal hydrogel formulation and deliver 
sodium diclofenac into systemic circulation in a controlled release manner.
Keywords: Amylose, Xanthan gum, Coprocessed excipient, Transdermal hydrogel, In vitro penetration, In vivo penetration.
INTRODUCTION
One aim of research and development of drug delivery systems is to 
minimize adverse side effects. A common type of pharmaceutical 
preparation is a transdermal drug delivery system, which delivers a drug 
through the skin into the systemic circulation. This system has many 
advantages over oral or injectable drug delivery systems, including 
avoidance of first-pass metabolism so that a drug can be administered 
with small therapeutic doses [1]. Moreover, transdermal delivery 
systems also can reduce undesirable side effects, such as ulceration of 
the gastrointestinal tract, provide easier administration, and increase 
patient compliance because of reduced dosing frequency [2]. A type of 
dosage form that can be used in transdermal drug delivery systems is 
a hydrogel.
Hydrogels consist of a three-dimensional structure that is able to absorb 
water or biological fluid in large amounts [1]. Moreover, hydrogels can 
contain drug molecules in a way that allows the drug to be released 
slowly [3]. To produce a hydrogel formulation, an excipient is required 
that is capable of forming a three-dimensional structure that is strong, 
flexible, and can modulate drug release. Excipients with these functional 
properties can be obtained through chemical and physical modification 
of the excipients. One excipient that can prolong drug release is a 
coprocessed excipient. Coprocessing is a method of mixing an excipient 
that aims to eliminate unwanted functional properties and maintain or 
improve the desired functional properties [4]. A coprocessed excipient 
is obtained by incorporating one of the excipients into the structure of 
other excipient particles through a physical process, such as codrying. 
Among the examples of excipients that can be used for controlled drug 
release formulations in the form of a hydrogel are high amylose starch 
and xanthan gum [5,6].
A study conducted by Surini described the development of amylose 
and xanthan gum excipients as a matrix for sustained-release tablet 
formulation [7]. The development included modification in crosslinking 
and coprocessing of the excipients. The resulting excipient was Co-CLA-
XG, which is a coprocessed excipient of xanthan gum and amylose that 
was previously cross-linked by sodium trimetaphosphate (STMP). In 
addition, CL-Co-A-XG was produced, which is a cross-linked excipient 
of coprocessed amylose and xanthan gum. The study used STMP as a 
crosslinking agent at concentrations of 6% and 12% [7]. In addition, a 
different variation of amylose and xanthan gum, namely, 1:1, 1:2, and 2:1 
were used. As a result, modified cross-linked and coprocessed excipients 
with ratio (amylose: xanthan gum) of 1:1, 1:2, and 2:1 for each Co-
CLA6-XG, Co-CLA12-XG, CL6-Co-A-XG, and CL12-Co-A-XG (12 excipient 
types) were obtained. The Co-CLA-XG excipients were a rough powder 
(such as fiber) that was voluminous, odorless, and slightly yellowish-
white. The CL-Co-A-XG excipients were fine granules, odorless, white, 
and slightly yellowish. From those results, the CL-Co-A-XG excipients 
were characterized by higher viscosity and flow properties than those 
of Co-CLA-XG. The 6% concentration of the cross-linked agent gave a 
greater gel strength of excipient than that of the 12% concentration. 
However, both types of excipients were assessed as suitable for 
controlled release of drugs because such excipients are characterized 
by high viscosity, high gel strength, and sufficient expansion ability [7].
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In this study, the excipients of Co-CLA6-XG, Co-CLA12-XG, 
CL6-Co-A-XG, and CL12-Co-A-XG were used with a 1:2 ratio of amylose 
and xanthan gum because that ratio is expected to form a solid 
compact gel. Evaluations of the transdermal hydrogel included physical 
organoleptic observations, preparation acidity (pH), preparation 
consistency and thickness, and determination of drug levels in the 
hydrogel. We also performed in vitro and in vivo penetration tests. The 
in vitro penetration test was performed using Franz diffusion cells to 
assess drug penetration through the skin [8]. The in vivo penetration test 
was performed in male Sprague-Dawley rats as the most representative 
method to assess drug incorporation into the systemic circulation.
METHODS
Materials
Amylose (Shangqiu Kangmedia Bio-Tech, China), xanthan gum (Cargill 
Bioengineering, Canada), diclofenac sodium (Yung Zip Chemical, 
Taiwan), STMP (Shangqiu Kangmedia Bio-Tech, China), sodium 
hydroxide (Merck, Germany), hydrochloride acid (Merck, Germany), 
sulfuric acid (Merck, Germany), nitric acid (Merck Germany), ascorbic 
acid (Takeda, Japan), orthophosphate acid (Merck, Germany), potassium 
dihydrogen phosphate (Merck, Germany), ammonium molybdate 
tetrahydrate (Merck, Germany), triethylamine high-performance liquid 
chromatography (HPLC) grade (Merck, Germany), methanol HPLC grade 
(Merck, Germany), and diltiazem hydrochloride (Piramal Healthcare, 
India) were used. Other chemicals and solvents were of analytical grade 
and purchased from commercial suppliers. Sprague-Dawley rats were 
obtained from Institut Pertanian Bogor (Bogor Agricultural University, 
Bogor, Indonesia).
Synthesis of Co-CLA6-XG and Co-CLA12-XG (1:2) (method A)
Synthesis method of cross-linked amylose and coprocessed excipient to 
give a cross-linked amylose-xanthan gum-based on Cury et al. [9], with 
modification as stated in Surini et al. [7]. The first stage was synthesis of 
cross-linked amylose by reacting amylose with STMP as a crosslinking 
agent. Amylose was dispersed in distilled water while stirring with a 
magnetic stirrer until perfectly dispersed. Sodium hydroxide 10 N 
solution was dripped slowly into the mass to maintain the pH at 11–12 
during the reaction. In another flask, STMP solutions were prepared to 
produce 6% b/v for CLA6 and 12% b/v for CLA12. Thereafter, the STMP 
solution was slowly added to the dispersion of amylose while stirring 
using a homogenizer (CKL Machinery, Malaysia) at a speed of 3000 rpm 
for 4 h and then allowed to stand for 12 h to ensure completion of 
the reaction. After that, the suspension of CLA was neutralized by 
hydrochloride acid 7N until a pH of six was achieved. The suspension 
washed with ethanol 96% v/v until the filtrate gave a negative result 
with ammonium molybdate reagent. The residues were dried at room 
temperature for 48 h. The dried residues were then sieved through a 
35-mesh (500-μm) sieve.
The second stage was coprocessing for each 3% CLA (CLA6 and 
CLA12) with 3% xanthan gum in distilled water in 1:2 ratio using a 
homogenizer (CKL Machinery) at 3000 rpm for 30 min. Thereafter, the 
mass was dried in a drum drier (R. Simon Dryers, UK) at a temperature 
of 109–112°C. The produced mass was mashed and sieved by a 
35-mesh (500-μm) sieve.
Synthesis of CL6-Co-A-XG and CL12-Co-A-XG (1:2) (Method B)
The first stage was a physical modification by coprocessing amylose with 
xanthan gum at a concentration of 3% for each in distilled water in 1:2 
ratio. The mass was mixed in a homogenizer (CKL Machinery) at 3000 rpm 
for 30 min to obtain a homogeneous mass. The homogeneous mass was 
dried in a drum drier (R. Simon Dryers) at a temperature of 109–12°C. The 
produced mass was mashed and sieved with a 35-mesh (500-μm) sieve. 
The second stage was crosslinking of the coprocessed amylose-xanthan 
gum using the same method as the first stage of method A.
Substitution degree (SD) of the excipients
The SD was determined by the colorimetry method [10] using two 
different solutions. The A solution was ascorbic acid 10%, and the B 
solution was ammonium molybdate tetrahydrate 0.42%. The sample 
was placed in a crucible and heated at 600°C for 3 h. The ash from 
the sample was dissolved in sulfuric acid 0.1 N solution and boiled 
for 10 min. The solution was then filtered by Whatman 40 paper and 
diluted with aquadest-sulfuric acid 0.1 N solutions (1:1). Then, the A 
and B solutions were added to the sample solution. A solution of the 
sample was mixed and incubated at 45°C for 20 min in a water bath; it 
was then immediately analyzed using a visible spectrophotometer at 
a wavelength of 820 nm. The interpretation of the phosphate SD was 
made by comparison with a calibration curve. The phosphate SD was 
calculated according to the following equation:
162PDS=
3100 102P−
where P is the percentage of phosphate from cross-linked high 
amylose [11], 162 is the molecular weight of a glucose unit, 3100 is 
the molecular weight of phosphate, and 102 is the molecular weight of 
phosphate as -PO3Na.
Preparation of transdermal hydrogels
The formulas of Co-CLA6-XG 1:2, Co-CLA12-XG 1:2, CL6-Co-A-XG 1:2, 
and CL12-Co-A-XG 1:2 transdermal hydrogels are shown in Table 1. The 
transdermal hydrogels containing diclofenac sodium were prepared 
by dissolving diclofenac sodium in propylene glycol, then adding it to 
polyethylene glycol (PEG) 400 and demineralized water. The hydrogel 
was mixed on a homogenizer at 1000 rpm until it became clear. The 
drug solution was homogenized in a sonicator for 10 min. Each excipient 
was dispersed in the drug solution and allowed to stand for 15 min. 
Subsequently, the mass was mixed in a homogenizer at 1000 rpm and 
50°C for 15 min to give a homogenous mass. Then, up to 75 g of the 
homogenous mass was placed into a 10×7.5-cm mold and dried in an oven 
at 50°C for 5 h. After cooling, the hydrogel was cut into 1×1-cm sections.
Evaluation of transdermal hydrogels
Evaluation of the transdermal hydrogels included surface pH, thickness, 
consistency, and drug content. The surface pH of the hydrogel was 
measured by placing the hydrogel in demineralized water for 2 h. 
The electrode of the pH-meter was then placed on the surface of the 
hydrogel until it reached equilibrium. The thickness of a transdermal 
hydrogel section was measured using a caliper. The consistency of the 
hydrogel was determined using a penetrometer (Herzoo, Germany).
Table 1: Formulation of transdermal hydrogel containing 
diclofenac sodium
Composition F1 F2 F3 F4 F5 F6 F7 F8
Diclofenac 
sodium (g)
5 0.5 5 0.5 5 0.5 5 0.5
Co-CLA6-XG (g) 5 5 - - - - - -
Co-CLA12-XG (g) - - 5 5 - - - -
CL6-Co-A-XG (g) - - - - 5 5 - -
CL12-Co-A-XG (g) - - - - - - 5 5
Polyethylene 
glycol 400 (g)
2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5
Propylene  
glycol (g)
7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5
Demineralized 
water ad (g)
100 100 100 100 100 100 100 100






Each point represents mean±standard deviation (n=3)
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The diclofenac sodium content in the hydrogel was determined using 
an ultraviolet (UV) spectrophotometer. Each hydrogel was dissolved 
in phosphate buffer pH 7.4. The solution was then homogenized in 
a sonicator to ensure that the diclofenac sodium was completely 
dissolved in the phosphate buffer pH 7.4. Hydrogel F1, F3, F5, and F7 
were diluted to 1/100 of their initial concentrations with phosphate 
buffer pH 7.4, and F2, F4, F6, and F8 were diluted to 1/10 of their initial 
concentrations with phosphate buffer pH 7.4. Each sample solution was 
measured by UV spectrophotometry at a wavelength of 276 nm. Each 
hydrogel was assayed 3 times.
In vitro penetration study
The methods used for animal sacrifice for in vitro and in vivo 
penetration studies were approved by the Ethics Committee of the 
Faculty of Medicine, Universitas Indonesia (approval no. 224/UN2.
FI/ETIK/2015). Sprague-Dawley rats were housed under standard 
conditions of temperature, relative humidity, and light. Unless 
otherwise specified, food, and water were given ad libitum.
The in vitro penetration test method was based on that of 
Klimes et al. [12] with slight modifications. The penetration of 
diclofenac sodium through the skin was measured using Franz diffusion 
cells. The receptor compartment was filled with a solution of phosphate 
buffer pH 7.4, and the temperature was maintained at 37±0.5°C. The 
speed of the magnetic stirrer was set to 250 rpm. The abdominal 
skins were collected from the Sprague-Dawley male rats, which were 
approximately 8 w old and weighed ±200 g. The skins were placed 
between the donor and the receptor compartment with the dermal side 
in contact with the receptor medium. The hydrogels (F1, F3, F5, and F7) 
were placed in the donor compartment. As much as, 0.5 ml of the sample 
solutions was withdrawn at each time interval from the receptor and 
immediately replaced with the same amount of pH 7.4 phosphate-
buffered solution. The amount of diclofenac sodium in the sample was 
then measured using a UV spectrophotometer (Shimadzu, Japan) at a 
wavelength of 276 nm.
In vivo penetration study
The method was based on Sintov and Botner [13] with slight 
modifications. The experiment used 8-w old Sprague-Dawley male rats 
(n=6) for each hydrogel (F2, F4, F6, and F8). The rats were anesthetized 
by intra-peritoneum injection of urethane (1000 mg/kg). The 
abdominal skins of the rats were shaved, and each hydrogel (F2, F4, F6, 
and F8) was placed on skin with plaster to keep the hydrogel on the 
surface of the abdomen during the test. As much as, 0.5 ml of a blood 
sample was collected from the sinus orbital of the eye at each time 
interval and then inserted into a microtube that had been loaded with 
heparin. Blood samples were centrifuged at 10,000 rpm for 20 min to 
separate the blood plasma from blood cells.
Analysis of diclofenac sodium in rat plasma
Diclofenac sodium in rat plasma was analyzed by HPLC (Shimadzu) 
equipped with a photometric diode array detector at a wavelength of 
283 nm. The 250×4.6 mm C18 reversed-phase column had a particle 
size of 5 µm. The mobile phase was a mixture of methanol: bidistilled 
water containing 1% triethylamine pH 6.5 by adding orthophosphoric 
acid (80:20) at a flow rate of 0.5 ml/min. Before analysis, as much as 
250 µl of plasma sample was added with 100 µl of internal standard 
(diltiazem hydrochloride 100 ppm) and mixed on a vortex mixer for 
10 s. Thereafter, the sample was added to 250 µl methanol HPLC grade 
and mixed on a vortex mixer for 2 min and centrifuged at 10,000 rpm for 
10 min to precipitate the proteins. Furthermore, as much as 20.0 µl of 
supernatant was injected into the HPLC instrument under the selected 
conditions. The method was partially validated by the European 
Medicine Agency [14].
RESULTS AND DISCUSSION
SD of the excipients
The SD was calculated as the degree of substitution of hydroxyl 
groups by phosphate groups from STMP in the amylose and xanthan 
gum. Inorganic phosphate was produced by heating the excipient to 
600°C. Inorganic phosphate was reacted with ammonium molybdate 
tetrahydrate in acid solution to produce a phosphomolybdate complex, 
which was then reduced by ascorbic acid to produce a blue color [15].
Table 2 shows the differences in the SD between the excipients. The SD 
values were determined for CLA6, CLA12, CL6-Co-A-XG, and CL12-Co-
A-XG. An SD of 0.08 indicated substitution of eight phosphate groups 
for hydroxyl groups in every 100 anhydroglucose units of amylose 
and/or xanthan gum. An SD of 0.10 indicated a substitution of 10 
phosphate groups for hydroxyl groups in every 100 anhydroglucose 
units of amylose and/or xanthan gum. CL6-Co-A-XG has ten phosphate 
groups, and CL12-Co-A-XG had an SD of 0.17 indicating 17 substituted 
hydroxyl groups in every 100 anhydroglucose units of amylose and/
or xanthan gum. From this data, we concluded that increasing the 
concentration of STMP increased the SD of the excipient. The SD of each 
excipient did not change its physical characteristics but did affect its 
functional characteristics, such as the swelling index, gelling strength, 
and viscosity, which could affect drug release [7].
Evaluation of transdermal hydrogels
Table 3 shows the evaluation results of the transdermal hydrogels’ 
properties, including surface pH, hydrogel thickness, consistency value, 
and drug content in each hydrogel. The surface pH of the transdermal 
hydrogel was in the range of the limits of skin pH (5.6–7.5), which 
indicated that the transdermal hydrogel would not cause local irritation 
of human skin [16]. The surface pH of the transdermal hydrogel also 
was affected by the other components, such as diclofenac sodium, 
PEG 400, and propylene glycol. As shown in Table 3, there is a slight 
Table 3: Properties of the transdermal hydrogels
Hydrogel Formula Surface pH Thickness (mm) Consistency (yield value)  Drug content in each hydrogel (mg)
Co-CLA6-XG F1 7.52±0.05 8.18±0.12 5537.71±102.09 48.15±0.59
F2 7.21±0.04 7.20±0.38 5679.59±434.79 5.36±0.05
Co-CLA12-XG F3 7.48±0.30 8.00±0.27 6150.01±171.85 48.03±1.45
F4 6.96±0.16 7.15±0.05 6002.12±422.85 5.19±0.13
CL6-Co-A-XG F5 7.18±0.12 7.55±0.20 5752.06±109.18 50.74±2.82
F6 7.35±0.14 7.40±0.33 6858.55±103.08 5.06±0.06
CL12-Co-A-XG F7 7.25±0.02 7.07±0.09 5578.43±207.51 50.82±0.88
F8 7.33±0.02 7.27±0.15 6386.91±614.70 5.06±0.06
Each point represents mean±standard deviation (n=3)
Table 4: Flux values and the cumulative amount of the 
penetrated drug
Hydrogel Formula J (µg.cm-2/h−1) Q (µg.cm−2) %Q
Co-CLA6-XG F1 655.23±116.43 7.629±711 23.66±4.10
Co-CLA12-XG F3 569.08±26.58 6.842±467 19.24±0.81
CL6-Co-A-XG F5 867.42±101.27 10.438±390 35.41±9.29
CL12-Co-A-XG F7 736.99±15.39 8,994±105 31.26±0.33
Each point represents the mean±standard deviation (n=3). J represents the 
transdermal flux, and Q is the cumulative amount of drug penetrated through 
the rat skin
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difference in thickness among the hydrogels, which is associated with 
water content in each hydrogel (data not shown). In addition, the 
produced transdermal hydrogels had a hard consistency according 
to Sherman [17]. The hardest consistency was observed for CL6-Co-
A-XG followed by CL12-Co-A-XG, Co-CLA12-XG, and Co-CLA6- XG. The 
produced transdermal hydrogels showed rigid form but still contained 
water. The drug content of diclofenac sodium in the transdermal 
hydrogel was evaluated by UV–visible spectrophotometry at 276 nm. 
Compared with the drug content in the initial formula, the transdermal 
hydrogels contained 95–105% of diclofenac sodium, because the F1, F3, 
F5, and F7 should contain ±50 mg for in vitro penetration study and the 
F2, F4, F6, and F8 should contain ±5 mg for in vivo penetration study.
In vitro penetration study
Fig. 1 shows the penetration profiles of diclofenac sodium from the 
transdermal hydrogels across through the rat skin membrane. The flux 
value and cumulative amount of drug that penetrated through the skin 
among the four hydrogels, comprising different polymers, are shown in 
Table 4. The diffusion of diclofenac sodium through the skin was passive 
with the concentration gradient as the driving force. The diffusion was 
affected by many factors, such as the solubility of diclofenac sodium and 
the thickness of the stratum corneum [18]. Diclofenac sodium in water 
solution can be hydrolyzed to diclofenac acid, which will increase the 
partition coefficient of the active substance so that the penetration of 
the drug can also be [14]. The mechanism of drug permeation through 
the skin begins by swelling of the hydrogel. The receptor compartment, 
which consists of phosphate buffer pH 7.4, caused hydration of the rat 
skin. The transdermal hydrogel, which consisted of a polymer matrix, 
could be wetted by absorbing fluid as it contacts the skin. This process 
causes the hydrogel to swell so that diclofenac sodium diffuses through 
the three-dimensional network of the polymer. During that process, the 
gradient concentration between the rat skin and hydrogel is high, which 
causes diclofenac sodium to permeate through the skin.
The highest cumulative amount of drug penetrated through the skin 
was achieved by the CL6-Co-A-XG 1:2 hydrogel (F5). The crosslinking in 
CL6-Co-A-XG (1:2) may occur between amylose and xanthan gum. The 
more crosslinking indicates high crosslinking density, which means the 
network was closely woven. In this case, the chain sections of the cross-
links were short and anchored by many points. Therefore, the polymer 
became less flexible and more rigid [19]. This characteristic makes 
diffusion of the drug easier through the matrix.
The Co-CLA6-XG 1:2 (F1) and Co-CLA12-XG 1:2 (F3) hydrogels 
gave levels of penetration of diclofenac sodium <30% because the 
three-dimensional networks of hydrogels F1 and F3 consisted of 
some closed-hydrogen bonds and high gel strength that slowed drug 
release [7]. Dumoulin et al. stated that drug release could be controlled 
by crosslinking amylose, the degree of which was limited in CLA-3 to 
CLA-11, and the maximum drug release time was observed in CLA-6 (as 
long as 20–24 h) [20]. Furthermore, Lanaerts et al. [20] stated that the 
increase in the degree of crosslinking from CLA-6 to CLA-20 correlated 
with the decrease in crystal properties, which can lead to a decreasing 
ability to form a double-helix structure and acceleration of matrix 
hydration [20].
The percentage of cumulative drug penetrations of all hydrogels 
through the skin was <50%, which was caused not only by the ability 
of the polymer to slow drug release but also the characteristics of the 
diclofenac sodium as a drug model. The low partition coefficient of 
sodium diclofenac (log p=0.70) was an important factor related to drug 
permeation because the partition coefficient indicates the ability of a 
drug to partition into hydrophobic and hydrophilic phases [21].
In vivo penetration study
Fig. 2 shows the mean of the plasma concentration-time profiles of 
diclofenac after transdermal administration for 12 h. The results show 
that the highest area under the curve (AUC) was achieved by F4 (Co-
CLA12-XG hydrogel), followed by the Co-CLA6-XG (F2), CL12-Co-A-XG 
(F8), and CL6-Co-A-XG (F6) matrices. However, the AUC value of F4 
was not significantly different than that of F2, (p>0.005). As presented 
Fig. 1: In vitro percutaneous penetration profiles of diclofenac 
sodium through excised rat skins after application of transdermal 
hydrogel prepared from different excipients. Green, purple, blue, 
and red lines represent F1, F3, F5, and F7, respectively. Each point 
represents the mean±standard deviation; n=3
Fig. 2: Plasma concentration-time profiles after transdermal 
administration of diclofenac-containing hydrogel for 
Co-CLA6-XG (F2), Co-CLA12-XG (F4), CL6-Co-A-XG (F6), and 
CL12-Co-A-XG (F8), as the matrix. Green, purple, blue, and 
red lines represent F2, F4, F6, and F8, respectively. Each point 
represents the mean±standard error; n=6
Table 5: Pharmacokinetic parameters of the transdermal hydrogels containing diclofenac sodium
Hydrogel Formula Cmax (µg/ml) Tmax (h) AUC0-12 (µg/ml h) Ke (h-1) t1/2 (h) MRT (h)
Co-CLA6-XG F2 4.35±0.94 1.00±0.00 32.08±5.40 0.10±0.03 11.47±4.04 16.66±5.86
Co-CLA12-XG F4 4.87±1.06 1.00±0.00 34.27±8.34 0.12±0.03 7.96±1.90 11.89±2.67
CL6-Co-A-XG F6 2.87±0.48 0.50±0.11 6.20±1.19 0.18±0.04 5.29±1.50 4.82±0.74
CL12-Co-A-XG F8 4.34±0.58 0.50±0.00 14.38±2.38 0.10±0.02 8.48±1.57 11.23±2.00
AUC: Area under the curve, MRT: Mean residence time, Ke: Elimination constant. Data are expressed as mean±standard error, n=6
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in Table 5, the AUC, Cmax, Tmax, t½, and mean residence time (MRT) 
values of the transdermal diclofenac hydrogel, comprising Co-CLA6-
XG as a matrix (F2), showed no significant difference (p>0.005) with 
F4, comprising Co-CLA12-XG. In contrast, the AUC of the transdermal 
hydrogel F6 and F8, comprising CL6-Co-A-XG and CL12-Co-A-XG, 
respectively, significantly decreased. The results indicated that the 
crosslinking degree of amylose and the method of preparation the 
excipient affected their drug delivery. In addition, the MRT and Ke 
values of the transdermal hydrogels of F2, F4, and F8 indicated that 
the produced excipients can be used as a transdermal matrix with 
controlled and prolonged release behavior.
CONCLUSION
For diclofenac sodium as the model drug, the in vitro and in vivo 
penetration study results indicated the feasibility of developing 
hydrogels using Co-CLA6-XG, Co-CLA12-XG, CL6-Co-A-XG, or 
CL12-Co-A-XG as a matrix former that could be used as a good 
transdermal dosage form. The results also show the ability of these 
hydrogels to provide good controlled release permeation of the active 
model drug. Comparison of the in vivo and in vitro skin penetration 
data in this study was difficult, but the results of both studies suggested 
that the hydrogel formulations would provide good controlled drug 
permeation through the skin. Further studies are needed to determine 
if these hydrogels can be used for humans in clinical studies.
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